Method of increasing bioavailability and/or prolonging ophthalmic action of a drug

US12409175B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12409175-B2
Application numberUS-202418441901-A
CountryUS
Kind codeB2
Filing dateFeb 14, 2024
Priority dateJul 28, 2014
Publication dateSep 9, 2025
Grant dateSep 9, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.

First claim

Opening claim text (preview).

The invention claimed is: 1. An aqueous suspension comprising reversible clusters of drug loaded ion-exchange resin particles, said clusters have a D50 value of at least 2 micrometers and the drug loaded ion-exchange resin particles have a particle size distribution characterized in that the D90 value is 70 to 900 nanometers, wherein the drug is brimonidine tartrate, and the brimonidine tartrate is present at a concentration of 0.35% w/v. 2. The aqueous suspension of claim 1 , wherein the ion-exchange resin is a cross-linked polystyrene with sulfonic acid groups. 3. The aqueous suspension of claim 1 , wherein the ion-exchange resin is sodium polystyrene divinyl benzene sulphonate. 4. The aqueous suspension of claim 3 , wherein the brimonidine tartrate is present at a concentration of 0.35% w/v and the sodium polystyrene divinyl benzene sulphonate is present at a concentration of 0.35% w/v. 5. The aqueous suspension of claim 1 , further comprising: (i) hydroxypropyl methylcellulose, (ii) polyvinylpyrrolidone, (iii) carbomer, and (iv) edetate disodium. 6. The aqueous suspension of claim 5 , further comprising: (v) benzalkonium chloride, (vi) N-laurylsarcosine sodium, (vii) mannitol, and (viii) tromethamine. 7. The aqueous suspension of claim 1 , comprising 0.35% w/v sodium polystyrene divinyl benzene sulphonate and further comprising: (i) 0.3% w/v hydroxypropyl methylcellulose, (ii) 1.2% w/v polyvinylpyrrolidone, (iii) 0.1% w/v carbomer, and (iv) 0.1% w/v edetate disodium. 8. The aqueous suspension of claim 7 , further comprising: (v) benzalkonium chloride, (vi) 0.06% w/v N-laurylsarcosine sodium, (vii) 4.5% w/v mannitol, and (viii) 0.32% w/v tromethamine. 9. The aqueous suspension of claim 1 , wherein the aqueous suspension has an osmolality of 250-375 mOsm/kg. 10. The aqueous suspension of claim 1 , wherein the aqueous suspension is suitable for once-a-day topical instillation. 11. A method of reducing elevated intraocular pressure in a patient in need thereof comprising topically administering once daily to an eye of the patient an aqueous suspension of claim 1 . 12. The method of claim 11 , wherein the patient suffers from glaucoma. 13. A method of reducing elevated intraocular pressure in a patient in need thereof comprising topically administering once daily to an eye of the patient an aqueous suspension of claim 6 . 14. The method of claim 13 , wherein the patient suffers from glaucoma.

Assignees

Inventors

Classifications

  • obtained by reactions only involving unsaturated carbon-to-carbon bonds · CPC title

  • obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title

  • Solutions {(composition of solutions A61K47/00)} · CPC title

  • Eye, e.g. artificial tears · CPC title

  • Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/5123) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12409175B2 cover?
The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution char…
Who is the assignee on this patent?
Sun Pharma Advanced Res Co Ltd
What technology area does this patent fall under?
Primary CPC classification A61K31/498. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).